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Abstract
BACKGROUND: Photochemotherapy is thought to be a novel therapeutic modality for cancer. The photobiomodulation 
(PBM), applied through high fluence low-level laser irradiation (HF-LLLI), can be combined with the chemotherapeutic 
drug cisplatin to gain the benefit of potentiating its cytotoxic effect at possibly lower doses.
AIM: The study aimed at investigation of the apoptotic effect of PBM, through LLLI (at HF), alone and in combination 
with cisplatin on cultured laryngeal cancer (HEp-2) cells.
MATERIALS AND METHODS: In the current experimental in vitro research, cultured laryngeal cancer cell line 
(HEp-2) was treated with the half maximal inhibitory concentration of cisplatin, with and without LLLI. The study design 
consisted of four groups: Control (untreated), cisplatin-alone-treated, PBM-alone-treated, and combination cisplatin 
+ PBM treated groups. Cells were irradiated once with diode laser (wavelength 808 nm, energy output 350 mW, 
3 min, fluence 190.91 J/cm2, and continuous wave mode). Cytotoxicity was assessed by 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide assay and the potential apoptotic effect was evaluated by cytochrome c (CYC) 
release through enzyme-linked immunosorbent assay (ELISA), in conjunction with visualization of cytomorphologic 
alterations by light microscopic examination, followed by digital morphometric analysis of nuclear changes through 
estimation of nuclear area factor (NAF). Analysis of variance and post hoc multiple-comparison tests were used for 
statistical analysis of the data of cytotoxicity assay, ELISA, and nuclear morphometric analysis.
RESULTS: PBM alone had a neutral effect on viability of HEp-2 cells, but it induced CYC release and lowered NAF 
mean value, significantly. When PBM was combined with cisplatin, more conspicuous deterioration in bioavailability 
of HEp-2 cells was observed, a higher amount of CYC was liberated and NAF value dropped in HEp-2 cells, 
compared to those which received separate treatments with cisplatin alone or PBM alone.
CONCLUSION: Based on the current findings, low-level laser photochemotherapy might be a promising adjunctive 
anticancer treatment for laryngeal cancer, as PBM at HF was able to augment the apoptotic effect of cisplatin on 
HEp-2 cancer cells.
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Introduction
Head and neck cancer (HNC), the sixth most 
common cancer in the world, is a grievous disease that 
claims as many as 300,000 lives each year, worldwide. 
Given the complexity of most head and neck anatomical 
sites, with consequent late detection and difficult surgical 
operability, the 5-year survival rate has been recently 
estimated to be ranging between 40% and 60% [1].
Cisplatin is a potent and widely used 
chemotherapeutic agent, being one of the first-line 
therapies for HNC [2]. Anticancer action of cisplatin is 
primarily mediated through induction of mitochondrial 
oxidative stress, leading to p53-dependent upregulation 
of proapoptotic Bax/Bak proteins, which allow for the 
exodus of cytochrome c (CYC) to the cytosol to further 
activate the executioner caspases 3, 6, and 7 of 
apoptotic death [3], [4].
Photobiomodulation (PBM) is a therapeutic 
approach that involves the use of LLL light in the 
visible red (600–700 nm) or near-infrared (NIR) (780–
1000 nm) spectrum, to induce biological alterations 
in the irradiated cells, through induction of a non-
thermal photochemical reaction [5]. PBM has been 
classically adopted as a photobiostimulatory treatment 
for alleviation of pain associated with inflammatory 
conditions [6]. However, the photobioinhibitory aspect 
of low-level laser irradiation (LLLI) was revealed, 
as the laser light was found to obey “biphasic 
dose-response” or Arndt–Schulz law, which states 
that: “Low-dose is stimulatory, and high-dose is 
inhibitory” [7]. Likewise, in PBM, low dose of LLLI, 
in terms of low fluence (J/cm2), is stimulatory, while 
high dose or high fluence LLLI (HF-LLLI) is inhibitory 
or even lethal [8]. This “hormetic” effect of LLLI was 
exploited as a possible anticancer approach in many 
studies, which did exhibit an obvious phototoxic effect 
of PBM [9], [10], [11]. Intriguingly, the apoptotic effect 
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exerted by PBM in prior studies was confirmed to be 
mitochondrially mediated [12], [13].
In the light of the fact that the mitochondrion 
represents a common target for both cisplatin- and 
PBM-mediated apoptosis, the present study aimed 
at investigating the potential synergistic phototoxic 
effect of PBM using HF-LLLI on cisplatin in a HNC cell 
line (HEp-2). The assessment of a possible apoptotic 
influence was at the molecular level by quantification of 
the amount of CYC released into the culture fluid after 
treatment, by enzyme-linked immunosorbent assay 
(ELISA), accompanied with direct visualization of PBM-
treated cells by light microscope to examine the probable 
apoptotic cytological features present. Moreover, 
confirmation of apoptosis as the principal mechanism 
of cell death in PBM-treated HEp-2 cells, either alone 
or in combination with cisplatin, was performed through 
a quantitative computer-based nuclear morphometric 
analysis, to estimate nuclear area factor (NAF), which 
is a function of both nuclear size and shape.
Materials and Methods
Cell culture
Human laryngeal squamous cell carcinoma 
cell line HEp-2 (ATCC® CCL-23™) used in this research 
work was kindly supplied from Cell Culture Department-
VACSERA, Egypt. HEp-2 cells were grown in Dulbecco’s 
modified eagle’s medium (Invitrogen/Life Technologies), 
supplemented with 10% fetal bovine serum (HyClone), 
2 mM glutamine and sodium bicarbonate and antibiotics 
(100 units/ml penicillin and 100 μg/ml streptomycin). The 
cultured cells were kept at 37°C in 95% air, 5% CO2, in 
a humidified incubator. Then, HEp-2 cells were passage 
through Trypsin-EDTA solution (0.25%) and phosphate-
buffered saline (PBS) (all were purchased from Sigma-
Aldrich, USA) and pH was maintained at 7.4.
Cisplatin treatment
Cisplatin drug (Sigma-Aldrich, USA) was 
supplied in a crystalline powder form, which was then 
dissolved in PBS to produce a stock solution of 5 mM 
concentration and subsequently diluted with culture 
medium to create a series of cisplatin concentrations 
(100, 25, 7.25, 1.56, and 0.39 μM). HEp-2 cells seeded 
in a flat-bottom 96-well plate were treated with the serial 
cisplatin concentrations for 24 h. Some HEp-2 cells 
remained untreated and served as control.
PBM
The laser device used in this experimental work 
was a NIR (808 nm) semiconductor LLL diode (Photon, 
Egypt). The output power was 350 mW and irradiation 
was adjusted to continuous wave mode (CW) for 3 min 
(180 s).The handpiece with a flat-top profile was held 
perpendicular and abutting the lid of the 96-well plate 
to deliver a homogeneous irradiation over each well, 
separately, in the darkness. Total energy conveyed to 
cells in each well, according to the equation: [Energy = 
irradiation time (seconds) X power (in watts)], equaled 
180 X 0.35 = 63 J. The irradiation area which was 
represented by growth space of the well, was measured 
to be 0.33 cm2. Hence, according to the equation: 
Fluence = energy/area, the fluence calculated was 
equivalent to 63/0.33= 190.91 J/cm2. Some cultured 
HEp-2 cells, which did not receive cisplatin treatment, 
but were only irradiated, were assigned as PBM group. 
HEp-2 cells which were cisplatin-treated for 24 h and 
then irradiated, constituted the combination group 
(Cis+PBM).
(3-[4,5-Dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide) (MTT) cytotoxicity 
assay
MTT cytotoxicity kit was purchased from 
Sigma-Aldrich, USA. This assay principally quantifies 
the viable fraction of cultured cells, based on their 
metabolic activity, as viable cells retain an active 
mitochondrial oxidoreductase enzyme that reduces 
the yellow tetrazolium salt in MTT solution into purple 
insoluble formazan crystals, which can be solubilized 
and quantified by spectrophotometric means. After 
incubation for 24 h, the cells were further incubated for 
4 h with 0.5 mg/ml MTT reagent. After that, when the 
purple dye was obvious, the MTT solubilization solution 
was added. Absorbance values in each well were 
determined, as the optical density (OD) was measured 
by ELISA microplate reader (ROBONIK P2000 EIA 
reader, India) at a wavelength range of 490–630 nm. 
The experiment was performed as 3-times repeats 
for each serial concentration, in both cisplatin-only 
treated HEp-2 cells (Cis) and Cis+PBM group. Besides, 
absorbance of PBM group as well as control cells was 
measured in triplicates. The absorbance mean of each 
group was calculated to be further used in the calculation 
of viability percentage, according to the equation [14]:
Viability % = (Absorbance mean of treated 
cells/absorbance mean of control cells) × 100
Calculation of half maximal inhibitory 
concentration (IC50) of cisplatin
The treatment of HEp-2 cells with cisplatin at 
the serial concentrations of 100–0.39 μM, with and 
without PBM, yielded values of viability % is shown in 
Table 1. The values of viability % obtained from MTT 
assay were exploited to calculate IC50 (the maximal 
inhibitory concentration that suppresses the growth 
of 50% of treated cells) of cisplatin, through plotting a 
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dose-response linear graph (Figure 1), depending on 
the equation y = ax + b, where the X-axis represents 
“the dose” or the logarithms of the cisplatin five 
graded concentrations (100, 25, 7.25, 1.56, and 0.39 
μM) and the Y-axis constituted “the response,” in 
the form of the corresponding values of viability %. 
The slope (a) and the intercept on Y-axis (b) were 
extracted from the plotted graph. The next step is 
substitution of (y) in the equation with the viability % 
(50%), to get the value of (x), which represents log of 
IC50 of cisplatin, from which IC50 is deduced. Another 
linear graph was plotted using values of viability % 
recorded after laser irradiation of cisplatin-treated 
cells (Cis+PBM), from which another IC50 should be 
obtained, to be compared with that obtained without 
PBM. The importance of plotting this second graph 
is that yielding a lower IC50 means a potentiating 
effect of PBM to cisplatin that caused it to inhibit 
growth of cancer cells at a lower dose. Nevertheless, 
the IC50 calculated from the cisplatin-only treatment 
was only prepared to be further used throughout the 
experiment.
Table 1: Values of viability % of MTT assay for cisplatin-alone 
(Cis) and combination - (Cis+PBM) treated HEp-2 cells at the 
serial concentrations100–0.39 μM
Cisplatin concentration (μM)
100 25 7.25 1.56 0.39
Cis 32.22 38.84 49.05 60.93 73.72
Cis+PBM 19.57 32.14 43.56 54.07 63.44
Plotted dose-response linear graphs (Figure 1) 
revealed that IC50 of cisplatin, with no subsequent LLLI 
was 7.08 μM, while IC50 calculated for combined 
cisplatin treatment and PBM was 2.437 μM.
Figure 1: Dose-response linear graphs for calculation of half 
maximal inhibitory concentration of cisplatin in: cisplatin-only 
treated HEp-2 cells (a) and in combination cisplatin+PBM treated 
HEp-2 cells (b)
a b
MTT assay was performed again (in 
triplicates), on two groups of cells; the first one was 
HEp-2 cells treated only with cisplatin at IC50 = 7.08 
μM (Cis group) and the second one was HEp-2 cells 
priorly incubated with cisplatin at IC50 = 7.08 μM, 
followed by PBM (Cis+PBM group). The recorded 
viability % data were compared to those of control and 
PBM groups.
ELISA
The levels of CYC released in cell culture fluid 
was assessed by the quantitative sandwich ELISA, 
using CYC human in vitro ELISA kit (#ab119521) 
(Abcam, UK). Briefly, CYC present in the sample or 
standard bound to the monoclonal (capture) antibody 
coating the wells. Then, the biotin-conjugated anti-CYC 
monoclonal (detection) antibody was added to bind CYC, 
which was at this moment sandwiched between the two 
antibodies. After incubation at room temperature for 2 h, 
rinsing with the washing buffer was carried out to wash 
away any unbound antibodies. After that, streptavidin-
horseradish peroxidase (HRP) conjugate solution was 
pipetted into the wells, with subsequent incubation for 
1 h at room temperature. Streptavidin engaged biotin of 
the detection antibody, which was bound to CYC in the 
sample or standard. Washing was then implemented to 
remove any unbound streptavidin-HRP. A chromogenic 
substrate, 3,3’,5,5’-tetramethyl benzidine (TMB), was 
added to the wells and left to react for 15 min at 37°C. 
A dark blue color developed, as HRP enzyme acted 
on the TMB substrate and the enzymatic reaction was 
terminated by adding the stop solution. The absorbance 
of both the samples and standards was measured by a 
microplate reader at 450 nm. All measurements were 
executed in triplicates.
The standard curve (Figure 2) was generated 
using the known CYC concentrations of the standards 
(on X-axis) and their measured OD on Y-axis. Hence, 
unknown CYC concentrations of the samples on X-axis 
were extrapolated through tracing their corresponding 
recorded OD values on Y-axis.
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Figure 2: Enzyme-linked immunosorbent assay standard curve for 
the estimation of cytochrome c concentration (pg/ml)
Microscopic examination
After slide preparation, hematoxylin and eosin 
(H&E) staining of the fixed cells was conducted as the 
slides were rehydrated by dipping them in descending 
concentrations of alcohol (100%, 90%, and 75% then 
50% ethanol), then were rinsed in distilled water for 
5 min. This was followed by immersing the slides 
in filtered Mayer’s hematoxylin solution for 3 min, 
succeeded by washing with distilled water twice. 
Afterward, the slides were immersed in eosin stain for 
5 s, followed by rinsing with distilled water. The stained 
slides were dehydrated by putting them in ascending 
concentrations of ethanol, and then were soaked in 
xylene for 10 min. The final step was adding one small 
drop of the mounting medium to the slide, and then 
placing a clean coverslip onto it. The slides were left to 
dry to get ready for examination.
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Assessment of H&E-stained HEp-2 cells
Cytological exploration and photomicrography
H&E-stained slides were photomicrographed at 
an original magnification power of ×100 (oil immersion) 
using a digital camera (EOS 650D, Canon, Japan) 
which was mounted on a light microscope (BX60, 
Olympus, Japan), in the Precision Measurement Unit, 
Oral Pathology Department, Faculty of Dentistry, 
Ain Shams University. The captured images were 
instantly stored on the computer system for further 
analysis. Microscopic fields showing the presence of 
the highest number of apoptotic cells were selected. 
The photomicrographs were carefully inspected for the 
morphological signs of cell death.
Nuclear morphometric analysis
The digital photomicrographs were analyzed 
using image analysis software (Image J, 1.41a, NIH, 
USA). Images were first corrected for brightness and 
contrast. Corrected images were then converted into 
8-bit grey scale type. Phase coloration of the darkest 
areas was automatically done. Thresholding was finely 
adjusted to mark the nuclei of HEp-2 cells. Finally, the 
nuclear circularity (Circ) and surface area (SA) were 
automatically measured. NAF was calculated according 
to the following formula [15].
Nuclear area factor = Circularity × Object area
Statistical analysis
Numerical data pooled from cytotoxicity assay 
in (the form of viability %), ELISA (in the form of CYC 
concentration in pg/ml), and nuclear morphometric 
analysis (in the form of NAF values) were tabulated in 
Microsoft Excel sheet, then inserted using the Statistical 
Package for the Social Sciences software, version 25.0 
(IBM Corporation, Armonk, NY, USA). Data were 
presented as mean ± standard deviation. Comparisons 
between groups were achieved using analysis of 
variance (ANOVA) with multiple comparisons post hoc 
test. p < 0.05 was considered statistically significant.
Results
MTT assay results
The recorded viability % data of all treatment 
groups are shown in Table 2 and illustrated in Figure 3.
ANOVA test showed a highly statistically significant 
difference in the mean viability % among all groups (p 
= 0.000). Post hoc multiple-comparison test revealed 
that the decrease in viability % after LLLI only in PBM 
group, compared to control group, was negligible 
and insignificant (p = 0.062). As regard the treatment 
groups Cis and Cis+PBM, there was a statistically high 
significant drop in mean viability %, in contrast to either 
control group or PBM group (p = 0.000). Interestingly, 
the decrease in mean viability % from Cis to Cis+PBM 
was statistically significant (p = 0.018).
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Figure 3: A bar chart showing the mean values of viability % of all 
study groups; control, PBM-only treated (PBM), cisplatin-only treated 
(Cis), and combination cisplatin+PBM (Cis+PBM)
ELISA results
The mean values of CYC concentration in all 
groups are demonstrated in Table 3 and Figure 4.
Table 3: Mean ± SD of CYC concentration (pg/ml) in all 
experimental groups; Control, PBM-only treated (PBM), 
cisplatin-only treated (Cis), and combination cisplatin+PBM 
(Cis+PBM)
CYC concentration Control PBM Cis Cis+PBM p-value
0.08a ± 0.01 0.19b ± 0.00 0.56c ± 0.01 0.63d ± 0.01 0.000*
*Significance is at p<0.05. Different superscripts mean that the statistical difference between groups is 
significant.
ANOVA test showed a highly statistically 
significant difference in the mean viability % among all 
groups (p = 0.000). Post hoc multiple-comparison test
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Figure 4: A bar chart demonstrating the mean values of CYC 
concentrations (pg/ml) in all study groups; control, PBM-only treated 
(PBM), cisplatin-only treated (Cis), and combination cisplatin+PBM 
(Cis+PBM)
demonstrated a high statistically significant increase in 
mean CYC concentration from control to PBM to Cis 
and finally to Cis+PBM (p = 0.000, between all). In other 
words, all modes of treatments in this work significantly 
Table 2: Mean ± SD of viability % of all experimental groups; 
control, PBM-only treated (PBM), cisplatin-only treated (Cis) 
and combination cisplatin+PBM (Cis+PBM)
Viability % Control PBM Cis Cis+PBM p-value
100a ± 0.0 93a ± 1.79 49.9b ± 3.56 41.3c ± 2.7 0.000*
*Significance is at p<0.05. Different superscripts mean that the statistical difference between groups is 
significant.
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boosted CYC release, in comparison toCYC basal level 
in control untreated HEp-2 cells.
Microscopic examination results
The microscopic findings obtained after close 
examination of digital photomicrographs of H&E-
stained HEp-2 cells in all groups are summarized in 
Figure 5.
Figure 5: A photomicrograph of (a)control group exhibiting fairly 
cohesive HEp-2 cells with cellular and nuclear variations in size/
shape (pleomorphism), along with hyperchromatism (red arrows); 
(b) PBM group showing apoptotic HEp-2 cells with a rounded 
up outline (green arrows), demonstrating peripheral chromatin 
condensation along with irregular nuclear outline (blue arrow), 
pyknotic nuclei undergoing nuclear fragmentation (red arrows), 
plasma membrane blebbing (orange arrow), and some intervening 
necrotic cells characterized by swollen cell bodies and oncotic 
lightly basophilic nuclei (black arrows); (c) Cis group displaying 
HEp-2 cells with chromatin margination (red arrow), generalized 
shrinkage in cell bodies with extensive membrane blebbing (blue 
arrow), budding of apoptotic body (green arrow), nuclear pyknosis 
with multifragmentation (black arrows), in addition to the presence 
of necrotic cells (yellow arrows) and cellular debris (asterisks); (d) 
Cis+PBM group displaying HEp-2 cells with a remarkable reduction 
in cellular size (red arrows), an extremely irregular outline due to 
brisk membrane blebbing (green arrows), apoptotic bodies formation 
(blue arrows), pyknotic nuclei with evident fragmentation in many of 
them (black arrows), and the presence of necrotic cells and cellular 
debris (asterisks) (H&E, ×1000 oil)
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Nuclear morphometric analysis results
An illustration of NAF estimation by Image J 
software is shown in Figure 6. The mean values of NAF 
of HEp-2 cells in all experimental groups are shown in 
Table 4 and Figure 7.
ANOVA test showed a highly statistically 
significant difference in the mean viability % among 
all groups (p = 0.000). Post hoc multiple-comparison 
test revealed a high statistically significant decrease 
in mean NAF in all treatment groups (PBM, Cis, and 
Cis+PBM) in comparison to control (p = 0.000). The 
reduction in mean NAF in both Cis and Cis+PBM 
groups was also high statistically significant in relation 
to PBM (p = 0.000). However, the decline in mean value 
of NAF recorded from Cis to Cis+PBMwas statistically 
nonsignificant (p = 0.252).
Table 4: Mean ± SD of NAF in all experimental groups; Control, 
PBM-only treated (PBM), cisplatin-only treated (Cis) and 
combination cisplatin+PBM (Cis+PBM)
NAF Control PBM Cis Cis+PBM p-value
26961.52a ± 
12277.27
22284.41b ± 
10965.43
5153.37c ± 
4468.03
3595.07c ± 
3480.95
0.000*
*Significance is at p<0.05. Different superscripts mean that the statistical difference between groups is 
significant.
Discussion
The conventional therapeutic approach for 
HNC entails surgical resection of operable tumors, 
followed by chemo/radiotherapy [16]. Cisplatin is 
one of the most potent cytotoxic chemotherapeutic 
drugs that can be introduced alone or in combination 
with other chemotherapeutics [17]. Unfortunately, 
cisplatin has a serious multi-organ toxicity profile that 
includes nephrotoxicity, ototoxicity, hepatotoxicity, 
and myelotoxicity [18]. Therefore, the treatment 
Figure 6: Nuclear morphometric analysis of HEp-2 cells by Image J 
software showing control cells (a); cells of PBM group (c); Cis group 
(e); Cis+PBM group (g) and their corresponding estimate of NAF (b), 
(d), (f) and (h), respectively
b
d
f
h
a
c
d
g
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paradigms of HNC are constantly evolving to improvise 
novel modalities that can attenuate the toxicities 
associated with the administration of high doses of 
chemotherapy. One of these emerging treatment 
approaches is laser photochemotherapy, which 
made the possibility of combining PBM (through the 
application of LLLI) and a potent cytotoxic agent like 
cisplatin a sought-after approach by investigators over 
the past decade [19], [20], [21], [22]. The literature, de 
facto, lacks enough consistency and clarity, regarding 
the assessment of PBM effect on different cancer cell 
lines, with many conflicting results due to variable 
dosimetry [23], [24], [25].
In the present study, PBM at remarkably HF 
(190.91 J/cm2) was combined with cisplatin treatment 
for the first time in literature and this was considered 
a safe approach that guaranteed that we have already 
bypassed the window of photobiostimulation, reported 
in the previous studies [23], [24].
Mitochondria are a common signaling hub 
for both cisplatin and PBM. The antitumor effect of 
cisplatin is fundamentally exerted through cross-linking 
mitochondrial DNA, to form non-functional adducts, 
causing transcription blockage and impaired synthesis 
of many electron transport chain (ETC) components. 
Subsequently, reactive oxygen species (ROS) build 
up to provoke a state of mitochondrial oxidative stress, 
leading to the release of CYC to the cytosol to activate 
the caspases accomplishing apoptotic death [4], [26]. 
The phototoxic effect of PBM was explained by Karu [27], 
who reported that LLLI brings about an overall shift 
in the intracellular redox status and tilts the balance 
toward greater oxidation. Likewise, when LLLI is 
operated at a high dose (fluence), Cox, the primary 
photoacceptor, will be overexcited and oxidated, to the 
extent that the enzyme fails to keep normal streaming 
of electrons. This theory was proved eventually in many 
studies [10], [11], [12], [13] which showed that HF-LLLI 
promote molecular rearrangements and conformational 
changes in Cox structure, rendering it functionless. 
Consequently, electrons in ETC accumulate, with the 
subsequent outbreak of ROS, giving rise to lethal 
oxidative stress that signals for mitochondrial apoptotic 
demise. Our result regarding significant CYC release 
in PBM-treated HEp-2 cells is in line with that obtained 
by Wu et al. [11] who irradiated lung adenocarcinoma 
ASTC-a-1 cells, at a fluence of 120 J/cm2.
In the current study, the synergistic effect of 
PBM to cisplatin was depicted during IC50 calculation, 
when the theoretically calculated value for cisplatin 
(with the use of graded concentrations) followed by 
PBM dropped to 2.4377 µM instead of 7.08 µM, which 
was deduced on individual cisplatin treatment. This 
provided early insight into the possible synergistic 
effect of PBM addition to cisplatin on HEp-2 cells. 
Moreover, MTT assay results confirmed this idea, as 
the combined cytotoxic effect of cisplatin and PBM was 
more significant than that achieved by cisplatin and 
PBM, when applied separately.
It is noteworthy to mention that it might seem like 
there was a discrepancy between the insignificant effect 
of PBM alone on viability of HEp-2 cancer cells and the 
significant influence of it on potentiating CYC levels in 
irradiated cancer cells. Nevertheless, Schalch et al. [28] 
explained this finding by the fact that the laser photons 
are capable of boosting the activity of some NADH-
associated mitochondrial dehydrogenases such as 
succinate dehydrogenase, affecting the oxidoreduction 
reaction of MTT assay. Besides, superoxide anions 
produced on PBM can directly reduce the tetrazolium 
salt into formazan, producing an overrated estimation 
of the viability fraction [29]. Therefore, it is highly 
recommended to use more than one method to assess 
viability in PBM-treated cells, like the neutral red test, 
which depends on the status of lysosomal activity [30].
Confirmation of the apoptotic effect of PBM in 
our study was done, first, through direct visualization 
of the apoptotic cytomorphologic changes, which 
predominated the scene and, second, through digital 
quantitative estimation of NAF, which is a direct 
function of nuclear circularity and nuclear SA [15]. 
PBM alone, compared to control, induced a significant 
decrease in NAF. This decrease was, at the same 
time, significantly less than that achieved by either 
cisplatin-only treatment or combination treatment. The 
photomicrographs reflected these findings, as there 
were mainly early apoptotic signs [31] in PBM group, 
in the form of rounding up of cells, nuclear shrinkage 
with irregular silhouette, chromatin margination, in 
addition to inconspicuous plasma membrane blebbing 
and nuclear fragmentation. On the other hand, Cis and 
Cis+PBM groups exhibited the full-blown morphology 
of apoptosis [31], with accentuated cellular/nuclear 
reduction in size and irregular outline, prominent 
membrane blebbing with active formation of apoptotic 
bodies and obvious nuclear pyknosis and fragmentation. 
However, comparing Cis to Cis+PBM, it was found 
that PBM did not add any significant cytomorphologic 
changes to those produced by cisplatin alone. This can 
be explained that PBM acts basically on the molecular 
level, as proved by significant stimulation of CYC 
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Figure 7: A bar chart showing the mean values of NAF in all study 
groups; Control, PBM-only treated (PBM), cisplatin-only treated 
(Cis), and combination cisplatin+PBM (Cis+PBM)
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release, but it might need more frequent application to 
allow such molecular alterations to be mirrored on the 
cytomorphological level.
All in all, cisplatin pre-treatment of HEp-2 cells 
is thought to represent the primary signal to apoptosis, 
and then subsequent PBM additionally floods the cell 
with ROS that further sensitize the cell to respond to 
cisplatin apoptotic stimuli. Moreover, given the fact that 
apoptosis is an energy-dependent process [32], so 
energy derived from PBM can be consumed up by the 
cellular death arsenal to execute the apoptosis program, 
as proposed by Diniz et al. [22]. One more mechanism 
postulated in a previous research stated that cisplatin is 
a heat- and light-activated chemical agent, so it may be 
activated by laser light [33].
Conclusion
Based on the current findings, low-level 
laser photochemotherapy might be a promising 
adjunctive anticancer treatment for laryngeal cancer, 
as PBM, performed through HF-LLLI, enhances the 
apoptotic effect of cisplatin on HEp-2 cells, as proved 
by augmentation of CYC release and induction of 
cytomorphological alterations, compatible with the 
apoptotic stigmata. PBM alone has also an apoptotic 
effect on HEp-2 cells. Hence, laser photochemotherapy 
may introduce a novel treatment modality for HNC, 
making the possibility of lowering cisplatin dosage 
plausible, through local control of the neoplasm by PBM, 
with consequent alleviation of the grave concomitant 
side effects. In this way, cisplatin-associated morbidity 
and mortality will be reduced, bringing hope to cancer 
patients for experiencing a better quality of life.
Recommendations
Despite the obvious apoptotic effect of PBM 
at HF, in addition to its anticancer enhancing effect on 
cisplatin treatment in HEp-2 cells, our results need to be 
further solidified and validated by intense future research 
in the area of photochemotherapy, using different 
dosimetry parameters and different HNC cell lines.
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